Here are three things to know.
1. Zilretta is administered as an intra-articular injection.
2. The non-opioid drug is intended to provide pain relief for patients with moderate to severe OA knee pain over a 12-week period.
3. Flexion expects Zilretta to hit the market by the end of the month.
More articles on supply chain:
FDA commissioner: High drug prices are a ‘public health concern the FDA should address’
Judge ruling allows drug ‘price gouging’ law to take effect in Maryland
Rite Aid names former Walgreens executive as president, COO
